Evestra Onkologia has takeen advantage of the innovative research accomplished at Evestra Inc., including issued composition of matter patents which describes EC317 and EC313 with applications in oncology and endometriosis. At a later stage, Evestra Onkologia will add to its portfolio additional highly innovative assets from Evestra, Inc., and from other third-parties which are involved in cancer and other proliferative diseases.
Currently there are two innovative compounds in Evestra Onkologia portfolio:
- EC317 – targeted breast cancer therapy indicated for BRCA1 breast cancer patients
- EC313– endometriosis